Relevant bibliographies by topics / Cell recipient

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cell recipient'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cell recipient.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cell recipient"

1

Fast, LD, CR Valeri, and JP Crowley. "Immune responses to major histocompatibility complex homozygous lymphoid cells in murine F1 hybrid recipients: implications for transfusion-associated graft-versus-host disease." Blood 86, no. 8 (1995): 3090–96. http://dx.doi.org/10.1182/blood.v86.8.3090.3090.

Full text
Abstract:
Abstract Graft-versus-host disease (GVHD) is currently encountered after bone marrow transplantation and transfusion. GVHD associated with transfusion (TA-GVHD) in apparently immunocompetent recipients has been recently reported with increasing frequency. A consistent finding in many of these cases is that the recipient received blood from a donor homozygous for one of the recipient's HLA haplotypes. However, the observed frequency of TA-GVHD is much lower than the estimated probability of this donor/recipient combination. The potential role of recipient immune responses in controlling TA-GVHD was investigated using an analogous murine model in which GVHD is induced by the injection of parental lymphoid cells into unirradiated F1 hybrid recipients. The effect of various immune manipulations of the recipient of GVHD induction was assessed by determining the number of donor lymphoid cells required to induce GVHD responses. Whereas depletion of recipient CD4+ cells increased the number of donor cells needed to induce GVHD, depletion of recipient CD8+ and natural killer cells resulted in fewer donor cells being needed to induce a GVHD response. These studies suggest a central role for functioning recipient CD8 and natural killer cells in the down-regulation of TA-GVHD development in recipients.
APA, Harvard, Vancouver, ISO, and other styles
2

Fast, LD, CR Valeri, and JP Crowley. "Immune responses to major histocompatibility complex homozygous lymphoid cells in murine F1 hybrid recipients: implications for transfusion-associated graft-versus-host disease." Blood 86, no. 8 (1995): 3090–96. http://dx.doi.org/10.1182/blood.v86.8.3090.bloodjournal8683090.

Full text
Abstract:
Graft-versus-host disease (GVHD) is currently encountered after bone marrow transplantation and transfusion. GVHD associated with transfusion (TA-GVHD) in apparently immunocompetent recipients has been recently reported with increasing frequency. A consistent finding in many of these cases is that the recipient received blood from a donor homozygous for one of the recipient's HLA haplotypes. However, the observed frequency of TA-GVHD is much lower than the estimated probability of this donor/recipient combination. The potential role of recipient immune responses in controlling TA-GVHD was investigated using an analogous murine model in which GVHD is induced by the injection of parental lymphoid cells into unirradiated F1 hybrid recipients. The effect of various immune manipulations of the recipient of GVHD induction was assessed by determining the number of donor lymphoid cells required to induce GVHD responses. Whereas depletion of recipient CD4+ cells increased the number of donor cells needed to induce GVHD, depletion of recipient CD8+ and natural killer cells resulted in fewer donor cells being needed to induce a GVHD response. These studies suggest a central role for functioning recipient CD8 and natural killer cells in the down-regulation of TA-GVHD development in recipients.
APA, Harvard, Vancouver, ISO, and other styles
3

Prokopchuk-Gauk, Oksana, Nicole L. Prokopishyn, Joanna McCarthy, and Meer-Taher Shabani-Rad. "Red Cell Alloimmunization Rates in Allogeneic Hematopoietic Stem Cell Transplant Recipients." Blood 128, no. 22 (2016): 3402. http://dx.doi.org/10.1182/blood.v128.22.3402.3402.

Full text
Abstract:
Abstract Introduction: Donor selection for allogeneic hematopoietic stem cell transplant (allo-HSCT) is dependent on matching with the intended recipient HLA allele profile, but not blood group compatibility. Red blood cell (RBC) phenotype matching is not considered, even if recipient alloantibodies are present pre-HSCT. Historically, up to 3.7% of allo-HSCT recipients have been found to develop new RBC alloantibodies following allo-HSCT. We completed an audit of all adult and pediatric allo-HSCT recipients of the Alberta Bone Marrow and Blood Cell Transplant Program to define the rate of RBC alloimmunization, and evaluate the impact of this RBC alloantibody presence on donor marrow engraftment in our allo-HSCT recipient population. Methods:A retrospective review was completed including all allogeneic pediatric and adult HSCT recipients between January 1, 2007 and January 1, 2015. Data was obtained from review of cellular therapy laboratory electronic records with red cell alloantibody information extracted manually from the transfusion medicine laboratory information system. Results: A total of 674 patients, including 104 pediatric recipients (<18 years old), underwent 697 allo-HSCT procedures (591 peripheral blood, 45 marrow, 61 cord blood). The mean HSCT recipient age was 40 (range 0-66) and most common HSCT indication was acute myeloid leukemia. Myeloablative conditioning was given to all adults and 86% of pediatric recipients. Fully HLA matched grafts were provided to 77% of recipients. ABO compatibility status of allo-HSCT procedures included the following: 362 (52%) ABO identical grafts, 154 (22%) grafts with a minor incompatibility, 143 (21%) grafts with a major incompatibility, and 38 (5.0%) grafts with bidirectional incompatibility. Rh mismatches were present in 165 (24%) of donor-recipient pairs. A total of 47 allo-HSCT recipients, including 3 pediatric and 44 adult patients, were found to have RBC alloantibodies before or after allo-HSCT. A total of 45 (6.4%) of allo-HSCT recipients had detectable RBC alloantibodies pre-HSCT, with 69 individual alloantibodies identified. The most common RBC alloantibody was anti-E (30%). Antibody screen results available on the day of or following HSCT in 43 allo-HSCT recipients found: 12 (28%) with antibody disappearance pre-HSCT and a negative screen on the date of allo-HSCT, 15 (35%) with antibody waning to disappearance after allo-HSCT, and 11 (26%) with persistence of pre-HSCT antibodies following allo-HSCT. New post-HSCT RBC alloantibodies were detected in 3 adult recipients of peripheral blood collected stem cell grafts (anti-D; anti-Kpa; anti-K plus anti-E), with an overall rate of 0.4%. These patients all received myeloablative conditioning and grafts which were ABO identical or had a minor ABO incompatibility. The anti-D antibody developed post-transplant in an Rh positive recipient of an Rh negative graft. Thus, the calculated overall rate of anti-D development in Rh mismatched HSCT recipients was 0.6%. There was no observed impact on neutrophil and platelet engraftment comparing adult allo-HSCT recipients who did and did not have pre-HSCT RBC alloantibodies. Conclusion: The risk of post-HSCT RBC alloantibody development is very low, even in Rh mismatched donor-recipient pairs. ABO incompatibility does not affect the risk of post-HSCT alloantibody development. Allo-HSCT recipients infrequently have pre-HSCT RBC alloantibodies, which may disappear after myeloablative conditioning. The presence of RBC alloantibodies pre-HSCT does not appear to impact donor marrow engraftment. The results of our retrospective study are limited by the availability, timing and frequency of post-HSCT antibody screen investigations. The decision to perform an antibody screen post-HSCT is a clinical one, typically dependent on recipient transfusion needs. Further prospective research is required to more accurately determine the rate of new post-HSCT alloantibody development and duration of alloantibody persistence or disappearance in allo-HSCT recipients. Results of these studies may also help guide RBC transfusion decisions in HSCT recipients known to have pre-HSCT RBC alloantibodies with proven engraftment and a negative post-HSCT antibody screen. Disclosures No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
4

Yahata, Takashi, Shizu Yumino, Yin Sheng, et al. "Clonal Evidence of Human Hematopoietic Stem Cell Hierarchy: Distinct SCID-Repopulating Cell Subsets Contribute to Various Phases of Hematopoiesis." Blood 108, no. 11 (2006): 1655. http://dx.doi.org/10.1182/blood.v108.11.1655.1655.

Full text
Abstract:
Abstract The SCID-repopulating cell (SRC) pool is shown to be heterogeneous and is composed of at least two distinct subsets; short-term and long-term repopulating cells (STRCs and LTRCs), which appear in different time points following transplantation. However, the precise characteristics and their relationships regarding the stem cell function remain elusive. To clarify the specific stem cell activity of each SRC clones that contribute to various stages of hematopoietic reconstitution, we examined the functional aspects of individual SRCs. To determine the repopulating dynamics of individual SRC clones in vivo, we traced the kinetics of individual SRC clones by LAM-PCR based virus integration site analysis. Individual SRC clones which repopulate in each NOG mouse that received EGFP-transduced fractionated CD34+ populations were analyzed at two time points. At 3 weeks after transplantation, BM cells were aspirated from tibia of each recipient, and at 18 weeks recipients were sacrificed and BM cells were recovered from 4 long bones. At each time point, EGFP-expressing human hematopoietic lineage cells were sorted for integration site analysis by LAM-PCR, and the fate of individual SRC clones in the same recipient was examined by clone-tracking analysis. Using primers that were designated based on the genomic sequence information of the CD33+ myeloid cell integration site, we clonally traced distribution of each clone in lineage cells; CD34+ stem/progenitor, T-, and B-lymphoid cells. We found that the early phase of hematopoietic reconstitution was attributed to transient myeloid-restricted clones which rapidly exhausted from the CD34+ stem cell pool. Interestingly, the multilineage cell-producing clones that were responsible for the later phase of hematopoiesis were distinct from the transient myeloid-restricted clones, and these clones continuously self-replicated in the CD34+ stem cell pool. Next, CD34+ cells from the primary recipients were divided into two secondary recipients, and the fate of individual SRC clones in different phases was traced using the paired secondary mice. One recipient was sacrificed at 3 weeks, and the other recipient was sacrificed at 18 weeks after secondary transplantation. First, clones that were detected at the early phase in one recipient were also detected at the later phase in the other recipient (80%). This is clonal evidence that LTRC in the primary recipient produces STRC as well as self-replicating secondary transplantable LTRC. Second, all clones in the secondary recipients were also detected in the primary donor; however, most of clones (68.3%) found in the primary recipients did not contribute to the secondary recipient. In addition, LTRC clones detected in the CD34+ stem cell pool of secondary recipient demonstrated much larger clone size compared to primary recipient. These indicated that the quiescent LTRC clones in the primary recipients were stimulated by transplantation, there by expanded clonally in the secondary recipient and contributed to the later phase of hematopoiesis. Our clonal tracking study clearly demonstrated that the hierarchical structure of the human HSC pool composed of distinct clonal subsets which were heterogeneous in the self-renewal capacity and differentiation ability.
APA, Harvard, Vancouver, ISO, and other styles
5

Zheng, Pingping, John Tamaresis, Govindarajan Thangavelu, et al. "Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant." Blood Advances 4, no. 17 (2020): 4232–43. http://dx.doi.org/10.1182/bloodadvances.2019000977.

Full text
Abstract:
Abstract Graft-versus-host disease (GVHD) is a complication of hematopoietic cell transplantation (HCT) caused by alloreactive T cells. Murine models of HCT are used to understand GVHD and T-cell reconstitution in GVHD target organs, most notably the gastrointestinal (GI) tract where the disease contributes most to patient mortality. T-cell receptor (TCR) repertoire sequencing was used to measure T-cell reconstitution from the same donor graft (C57BL/6 H-2b) in the GI tract of different recipients across a spectrum of matching, from syngeneic (C57BL/6), to minor histocompatibility (MHC) antigen mismatch BALB.B (H-2b), to major MHC mismatched B10.BR (H-2k) and BALB/c (H-2d). Although the donor T-cell pools had highly similar TCR, the TCR repertoire after HCT was very specific to recipients in each experiment independent of geography. A single invariant natural killer T clone was identifiable in every recipient group and was enriched in syngeneic recipients according to clonal count and confirmatory flow cytometry. Using a novel cluster analysis of the TCR repertoire, we could classify recipient groups based only on their CDR3 size distribution or TCR repertoire relatedness. Using a method for evaluating the contribution of common TCR motifs to relatedness, we found that reproducible sets of clones were associated with specific recipient groups within each experiment and that relatedness did not necessarily depend on the most common clones in allogeneic recipients. This finding suggests that TCR reconstitution is highly stochastic and likely does not depend on the evaluation of the most expanded TCR clones in any individual recipient but instead depends on a complex polyclonal architecture.
APA, Harvard, Vancouver, ISO, and other styles
6

Ruggeri, Loredana, Marusca Capanni, Myriam Casucci, et al. "Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation." Blood 94, no. 1 (1999): 333–39. http://dx.doi.org/10.1182/blood.v94.1.333.413a31_333_339.

Full text
Abstract:
Because of the expression of inhibitory receptors (KIR) for major histocompatibility complex (MHC) class I allotypes, a person’s natural killer (NK) cells will not recognize and will, therefore, kill cells from individuals lacking his/her KIR epitopes. This study investigated the role of NK cell alloreactivity in human HLA haplotype-mismatched hematopoietic stem cell transplantation and, specifically, the role of the three major NK specificities, ie, those for HLA-C group 1, HLA-C group 2, and HLA-Bw4 alleles. In 20 of 60 donor-recipient pairs, KIR epitope incompatibility and functional analyses of donor NK cell clones predicted donor NK cells could cause graft-versus-host (GVH)/graft-versus-leukemia (GVL) reactions. NK cell clones of donor origin were obtained from transplanted recipients and tested for lysis of recipient’s cryopreserved pretransplant lymphocytes. Despite the absence of GVH disease, we detected high frequencies of NK clones which killed recipient’s target cells. Lysis followed the rules of NK cell alloreactivity, being blocked only by the MHC class I KIR epitope which was missing in the recipient. The alloreactive NK clones also killed the allogeneic leukemia. Transplants from these KIR epitope incompatible donors had higher engraftment rates. Therefore, a GVL effector and engraftment facilitating mechanism, which is independent of T-cell–mediated GVH reactions, may be operational in HLA mismatched hematopoietic cell transplants.
APA, Harvard, Vancouver, ISO, and other styles
7

Stockwell, Sally, Muren Herrid, Rhonda Davey, Alan Brownlee, Keryn Hutton, and Jonathan R. Hill. "Microsatellite detection of donor-derived sperm DNA following germ cell transplantation in cattle." Reproduction, Fertility and Development 21, no. 3 (2009): 462. http://dx.doi.org/10.1071/rd08130.

Full text
Abstract:
Although autologous and heterologous transplantation has resulted in colonisation of recipient testes in cattle, the ability of the transplanted spermatogonial stem cells to complete spermatogenesis has not yet been determined. The objective of the present study was to identify and validate microsatellite markers that can distinguish the genotype of different individuals and therefore can be used to detect the presence of donor DNA in recipient semen samples. In a previous study by this group, successful colonisation of recipient testes by heterologous transfer using a fluorescent dye was shown. In the present work, some of the same recipient animals were investigated further to monitor donor-derived sperm production. The bovine microsatellite detection method was developed specifically to test the ejaculates of the recipients and can also be used to pre-match individuals before germ cell transplantation. Semen was collected from the recipients 52–98 weeks after transfer and the presence of donor DNA in the samples was determined using microsatellite markers. In one of the recipients, all collected semen samples were shown to be positive for donor-derived cells; however, the percentage of donor spermatozoa in the recipient ejaculate declined with time. The donor DNA was also detected in both single cell suspensions and testis tissue from this recipient. These results demonstrate for the first time that testicular germ cell transplantation between different breeds of cattle is feasible and the recipients thereof are able to produce spermatozoa of donor origin. This technology has potential applications in livestock breeding systems and may provide an alternative to artificial insemination.
APA, Harvard, Vancouver, ISO, and other styles
8

Steele, D. J., T. M. Laufer, S. T. Smiley, et al. "Two levels of help for B cell alloantibody production." Journal of Experimental Medicine 183, no. 2 (1996): 699–703. http://dx.doi.org/10.1084/jem.183.2.699.

Full text
Abstract:
We have examined whether T cell stimulation by direct or indirect pathways contributes to alloantibody production by B cells after major histocompatibility complex (MHC)-disparate skin graft rejection in mice. Experiments were performed using normal mice, MHC class II-deficient mice, MHC class II-deficient mice with an intact peripheral CD4+ cell population (due to expression of class II antigens only on thymic epithelium), mice lacking the cytoplasmic tail of their MHC class II antigens, and mice depleted of CD4+ cells by anti-CD4 monoclonal antibody treatment. Depletion of recipient CD4+ cells reduced alloantibody production to barely detectable levels. Absence of donor MHC class II antigens did not affect the production of either immunoglobulin (Ig)M or IgG antibodies directed at class I alloantigens. Absence of recipient MHC class II antigens, however, led to production of only IgM but not IgG antibodies, even if the recipients had an intact CD4+ cell population. Absence of the cytoplasmic tail of the recipient's MHC class II antigens led to the production of slightly reduced amounts of IgG antibody. These findings indicate that (a) CD4+ cells are essential helper cells for B cell alloantibody production; (b) production of IgM alloantibody can occur with help from CD4+ cells, which recognize either donor class II antigens or modified recipient class II antigens; (c) isotype switching from IgM to IgG alloantibody requires help from CD4+ cells activated by antigens presented by recipient MHC class II molecules; and (d) the cytoplasmic domain of the recipient MHC class II molecules may be involved in the mechanism that leads to isotype switching by B cells. Thus, there are two levels of CD4-mediated help available for B cells responding to alloantigens: one (involving a noncognate interaction) can produce B cell activation, and a second (involving a cognate interaction) is required for differentiation and IgG alloantibody production.
APA, Harvard, Vancouver, ISO, and other styles
9

Ueda, Masumi, Lan Beppu, Judy Campbell, Mary E. D. Flowers, Jerald P. Radich, and Rainer Storb. "Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation." Blood 134, Supplement_1 (2019): 702. http://dx.doi.org/10.1182/blood-2019-126979.

Full text
Abstract:
After allogeneic hematopoietic cell transplantation (HCT), a relatively small number of donor hematopoietic cells must reconstitute the entire recipient hematopoietic system, while the donor is left with a near normal pool of hematopoietic cells. We hypothesized that the increased replicative demand on donor cells in the recipient after allogeneic HCT will accelerate telomere shortening and magnify the genetic alterations that are associated with normal aging, including clonal hematopoiesis. We aimed to compare mutation frequency in genes associated with clonal hematopoiesis of indeterminant potential (CHIP) and myeloid diseases between donors and recipients, with a focus on transplant pairs with older donors. We obtained contemporary blood samples from 10 related donor-recipient pairs surviving a median of 36.6 years (range 6.6-45.7 years) after HCT. Information on donor-recipient pairs is summarized in Table 1. Variant libraries were prepared from bulk peripheral blood mononuclear cells (PBMCs) using Archer Dx VariantPlex Myeloid panel of 75 myeloid disease-associated genes (ArcherDx, Boulder, CO). Sequencing was completed on the Illumina HiSeq system. Variants with allelic frequency (AF) ≥2% were detected in donors (median number of variants 50.5, range 35-107) and recipients (median number of variants 50, range 32-109). In all pairs, there was significant overlap in the variants detected, although some were unique to donors or recipients (Figure 1). Two of the 3 donor-recipient pairs with >25 years difference in donor age (84 and 71 years) and recipient age (47 and 42 years) showed an increase in the shared variant AF in the recipient in DNMT3A (nonsense and frameshift mutations) of 5 to 18% and 5 to 16%, respectively. All other shared variants in CHIP-associated genes (DNMT3A, ASXL1, TET2) detected in 6 pairs did not show significant difference in AF (Table 2). Among other shared variants of non-CHIP genes, 7 pairs showed mutations with ≥5% difference in AF, but the difference was small (mean difference 5.3%, range 4.5-7.4%) (Table 3). In conclusion, our results suggest that even decades after transplantation and high replicative demand, most donor variants, at the level of detection of this assay, do not preferentially expand in the recipient. Donor-recipient pairs with older donors and ~30-year difference in age with the recipient showed a modest expansion in DNMT3A clones. Future studies will compare contemporary samples to historical samples from the time of transplant. Disclosures Radich: Novartis: Other: RNA Sequencing; TwinStrand Biosciences: Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
10

Storek, Jan, Federico Viganego, Monja A. Dawson, et al. "Factors affecting antibody levels after allogeneic hematopoietic cell transplantation." Blood 101, no. 8 (2003): 3319–24. http://dx.doi.org/10.1182/blood-2002-05-1376.

Full text
Abstract:
AbstractTo obtain insight into the mechanism(s) of posttransplantation humoral immunodeficiency, we evaluated factors affecting serum antibody levels against polio, tetanus, Haemophilus influenzae, andStreptococcus pneumoniae in 87 patients. Patients with hematologic malignancies were randomized to receive marrow versus blood stem cells, which contain approximately 10 times more lymphocytes than marrow. Blood stem cell recipients did not have higher antibody levels than marrow recipients. Recipient pretransplantation antibody levels were correlated with the posttransplantation levels, especially in the first 6 months after transplantation when the correlation coefficients typically exceeded 0.6. Donor pretransplantation antibody levels had less of a correlation with posttransplantation levels in the recipient. Patient or donor age, total body irradiation, and graft-versus-host disease or its treatment appeared to have no effect. In conclusion, antibody levels in the first year after transplantation are affected primarily by pretransplantation antibody levels in the recipient and, to a lesser degree, in the donor. These findings suggest that immunization of the recipient and the donor before transplantation may be more effective in improving antibody immunity after transplantation than manipulating graft-versus-host disease, changing conditioning, or increasing the number of lymphocytes in the graft.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cell recipient"

1

Blais, Debbie Lin Marie. "Becoming an islet cell allotransplant recipient." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp04/mq21258.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jansson, Monika. "Detection of donor cells in recipient tissues after stem cell transplantation using FISH and immunophenotypi Stem cell transplantationng /." Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-222-4/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sivaganesh, Sivasuriya. "Recipient DCs presenting intact and processed MHC alloantigen mediate CD8⁸ T-cell responses." Thesis, University of Cambridge, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.609327.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lee, Joon. "The effects of adult progenitor cell transplantation on recipient cardiomyocyte excitation-contraction coupling." Thesis, Imperial College London, 2008. http://hdl.handle.net/10044/1/4250.

Full text
Abstract:
Cell transplantation is a promising strategy for treating heart failure but the mechanisms effecting functional improvements remain unknown. The hypothesis that cell transplantation influences the contractile properties and excitation-contraction (EC) coupling of recipient cardiomyocytes by paracrine mechanisms was tested. Adult rats underwent myocardial infarction and subsequently developed chronic heart failure. They then received intra-myocardial injections of either skeletal myoblasts or bone marrow mononuclear cells which were harvested from transgenic rats constitutively expressing green fluorescent protein. Four weeks after injection, both cell types increased ejection fraction and reduced cardiomyocyte size. Isolated cardiomyocytes emitted low levels of green fluorescence, indicating that they originated from the recipient heart. The cardiomyocytes were then studied using sarcomere length measurements, indo-1 fluorescence and whole-cell patch-clamping techniques. Injection of either bone marrow cells or skeletal myoblasts normalized the impaired contractile performance and the prolonged time-to-peak of the Ca2+ transients that were observed in failing cardiomyocytes. The smaller and slower L-type Ca2+ current observed in heart failure returned to normal values after skeletal myoblast, but not bone marrow mononuclear cell, transplantation. Analysis of Ca2+ sparks in isolated cardiomyocytes using confocal microscopy revealed that SR Ca2+ leak had increased in failing cardiomyocytes, but was normalized by skeletal myoblast transplantation. In order to test the hypothesis that these effects observed in vivo are mediated by paracrine substances secreted from the transplanted cells further experiments were performed. Cardiomyocytes were isolated from failing hearts and cultured for 48 hours. Co-culturing with either skeletal myoblasts or bone marrow mononuclear cells during this period improved cardiomyocyte contraction and Ca2+ handling. This effect was maintained even when the different cell populations were mechanically separated by means of a porous membrane, demonstrating that cell-to-cell contact was not required and that soluble substances mediated the effect. Analysis of the supernates obtained from these co-culture experiments identified four candidate substances as possible mediators, but confirmation of their importance requires further experimental investigation. In addition to the work described above, experiments were performed during the preparation of the whole-cell patch-clamping system. The system was tested by measuring the Na+/Ca2+ exchanger current densities in cardiomyocytes isolated from normal rat hearts. Using this system the acute effects of various -adrenergic agonists was assessed. The results obtained from this separate study are presented in Chapter 6.
APA, Harvard, Vancouver, ISO, and other styles
5

Beattie, Sara Margaret. "The Psychosocial Impact of Being a Caregiver and a Care Recipient During a Hematopoietic Stem Cell Transplant." Thesis, Université d'Ottawa / University of Ottawa, 2014. http://hdl.handle.net/10393/31443.

Full text
Abstract:
Hematopoietic stem cell transplant (HSCT) is a demanding cancer treatment for HSCT recipients and their caregivers. The thesis objectives were to (a) critically review the literature evaluating the psychosocial impact of being a caregiver to a HSCT patient; (b) evaluate a conceptual framework to examine the individual and dyadic experience of HSCT patients and their caregivers; and (c) gain a better understanding of how couples navigate the HSCT. Study 1 was a comprehensive literature review that demonstrated that caregiver distress is highest pre-HSCT and predictors of caregiver distress include female gender, elevated subjective burden, and higher patient symptom distress. This study also highlighted the need for theoretically driven research that examines reciprocal relationships between HSCT dyads. Study 2 proposed a conceptual model based on equity theory to examine the individual and dyadic experience of HSCT dyads that includes feelings of inequity, patient self-perceived burden (SPB), caregiver burden and distress. A cohort study with 72 HSCT patient-spousal caregiver dyads was conducted pre-HSCT. Questionnaire data was subjected to path analysis. Consistent with the model, pre-HSCT caregiver burden mediated the relationship between caregiver underbenefit and caregiver distress. Patient overbenefit was related to patient SPB, patient distress, and caregiver burden. Overall, the theoretical framework appeared to describe patient and caregivers individual experience of distress pre-HSCT, but did not as clearly encompass the dyadic experience of distress. Study 3 was a qualitative study of patient-caregiver dyads to gain insight on how some successfully navigate, whereas others have difficulties. One year post-HSCT five patient-caregiver dyads were interviewed separately (N =10). Five themes emerged. While all couples adopted patient and caregiver roles, four demonstrated effective adaptation whereas one couple experienced difficulties. Ongoing physical limitations, lack of mutual empathy and relational awareness, limited social support, and poor communication were associated with difficulty adjusting to the HSCT. This thesis provides a greater appreciation of the psychosocial challenges the patients and caregivers are experiencing and highlights that the experience of HSCT recipients and caregivers is unique and intertwined. Importantly, this thesis identifies current knowledge gaps in care of HSCT dyad, discusses its clinical implications and suggests avenues for future research.
APA, Harvard, Vancouver, ISO, and other styles
6

Oviedo, Victoria Rossmary Santacruz. "Produção de tomate em função da idade da muda e volume do recipiente." Universidade de São Paulo, 2007. http://www.teses.usp.br/teses/disponiveis/11/11136/tde-04042008-142551/.

Full text
Abstract:
Com o objetivo de avaliar as mudas e a produção de tomate (Lycopersicon esculentum Mill), tipo italiano \'Netuno\', no campo desenvolvidas em diferentes tipos de volume de recipiente com a combinação de varias idades de transplante foi conduzido este experimento no Departamento de Produção Vegetal da Escola Superior de Agricultura ¨Luiz de Queiroz\", Universidade de São Paulo, no município de Piracicaba - Estado de São Paulo, entre abril a agosto de 2005. Foram utilizadas bandejas de 72, 128, 288 e 450 células, com volumes celulares de 121,2; 34,6; 12,0 e 14,0 cm3 respectivamente. As idades de avaliação foram aos 19, 24, 29 e 34 dias após a semeadura. O delineamento experimental utilizado foi o de blocos casualizados, no esquema fatorial de 4 x 4. Um dos fatores foi representado pelas diferentes bandejas, e o segundo fator, pelas diferentes idades de avaliação. Na produção de mudas foram avaliadas, número de folhas, área foliar, altura da muda, massa fresca e seca de parte aérea e raiz e qualidade visual das mudas. Logo após o transplante foram avaliadas características de desenvolvimento vegetativo: área foliar, número de folhas, altura das plantas, diâmetro da haste, massa fresca de folhas e raiz e qualidade visual das plantas. Posteriormente durante a colheita foram avaliadas características de produção; precocidade, massa e número comercial de frutos, massa e número total de frutos. Também foi realizada a seleção dos frutos em pequenos, médios e grandes. Na comparação entre os tratamentos foram observadas algumas diferenças em algumas características. Os volumes maiores apresentaram melhor qualidade de mudas (121,2 e 34,6 cm³) e os volumes menores apresentaram mudas estioladas, raquíticas, desuniformes. Os volumes maiores apresentaram maior área foliar, massa fresca e seca de raiz. A melhor idade para o transplante foi de 24 e 29 dias para os volumes maiores, recomendando-se o volume de célula de 34,6 cm³. Com relação aos resultados de produção de frutos, não houve diferencia entre os tratamentos utilizados, porém, obteve se precocidade na colheita de frutos com volumes maiores. A muda de 24 dias teve o maior número e massa media de frutos por planta nas colheitas precoces. Número comercial e total de frutos foi maior nas idades de 19, 24 e 29 dias. As idades mais precoces e os volumes maiores apresentaram maior número e massa de frutos médios por planta. Não houve diferença para frutos grandes em todos os tratamentos estudados.<br>This study was carried out from April to August, 2005, Piracicaba, Sao Paulo State, Brazil. The objective of this work was to evaluate the effect of the cell recipient and seedlings age on the quality of transplants and tomato (Lycopersicon esculentum Mill) production \'Netuno\' in open field. The treatments resulted from the combination of for tray cell sizes 121,2; 34,6; 12,0 e 14,0 cm3 and four transplanting ages (19, 24, 29 e 34 days). It done in a randomized block design ( 4 x 4 factorial). One of the factors was represented by different cell volume and the second factor was transplants age. In the transplant production was evaluated, number of leaves, leaf area, fresh and dry leaves and root mass, seedlings quality (before production was evaluated the same vegetative characteristics) and after transplanting, the earliness, and total yield fruits (number and mass of fruits commercial fruits). The fruits were classified in small, medium and large sizes. The larger volumes (121, 2 e 34, 6 cm³) presented better quality of seedlings than of smaller one (12, 0 e 14, 0 cm³). There was etiolated, stunted, desuniformity, and the cell volume of 12,0 cm³ seedlings was yellows and small. The larger volumes presented higher fresh and dry mass. The better age for transplanting was 24 to 29 days for the larges volumes, being recommended the volume of cell of 34,6 cm³. No significant differences were observed between all treatments for fruits production, however, earliness in larger volumes was observed. Transplants with 24 days age were most productive for earliness. Commercial and total fruits number per plant increment at 19, 24 and also 29 days age. Transplants with 19, 24 days age and larger cell volumes had increased the number and mass of early fruits. The earliness age and the larger cell volume presented higher number and mass of medium fruits. There were not differences for larger fruits for all treatments.
APA, Harvard, Vancouver, ISO, and other styles
7

Kinch, Amelie. "Posttransplant Lymphoproliferative Disorders : Studies of Epstein-Barr Virus, Regulatory T Cells and Tumor Origin." Doctoral thesis, Uppsala universitet, Infektionssjukdomar, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-234130.

Full text
Abstract:
Epstein-Barr virus (EBV) infects almost all humans and establishes lifelong latency in B cells. Posttransplant lymphoproliferative disorder (PTLD) is a rare but serious complication after transplantation triggered by immunosuppression and often related to EBV infection. The aim of this thesis was to study the role of EBV in relation to clinical and histological features of PTLD, regulatory T cells (Tregs), and donor or recipient origin of PTLD. EBV surveillance after allogeneic hematopoietic stem cell transplantation (allo-HSCT) showed that EBV reactivations were common, but that symptomatic EBV disease (including PTLD) only occurred in the high-risk group (unrelated or mismatched related grafts, reduced-intensity conditioning). A threshold of 1000 copies/ml plasma distinguished EBV disease from asymptomatic reactivations. In a population-based cohort of 135 PTLDs/lymphomas after solid organ transplantation (SOT) almost half were EBV–. EBV+ PTLDs were associated with B cell phenotype, non-germinal center subtype of diffuse large B cell lymphoma (DLBCL), early-onset, graft involvement, antithymocyte globulin treatment, and younger age. EBV– PTLDs were associated with T cell phenotype, bone marrow involvement, and hepatitis C. Most PTLDs displayed few or no intratumoral Tregs with the marker FoxP3, possibly due to heavy immuno­suppres­sion. Half of both FoxP3+ and FoxP3– PTLDs were EBV+. FoxP3+ PTLDs were associated with B cell phenotype and hepatitis C. All PTLDs for which tumor origin could be determined were recipient-derived and half of them were EBV+. Eight of twelve recipient-derived graft PTLDs were disseminated outside the graft. T cell PTLD and hepatitis C were independently associated with inferior overall survival, whereas subtype of DLBCL, FoxP3-expression, and EBV-status did not influence survival. In conclusion, monitoring of EBV DNAemia in high-risk patients after allo-HSCT and pre-emptive therapy is valuable for prevention of PTLD. Use of anti­thymocyte globulin increases the risk for EBV+ PTLDs after allo-HSCT and SOT. With long follow-up time, a large proportion of PLTDs after SOT are EBV– with a different clinical presentation. Tregs are rare in PTLD and do not affect survival. The vast majority of PTLDs after SOT is of recipient origin. Graft PTLDs are more likely recipient-derived if disseminated. EBV-status is not associated with intratumoral Tregs or PTLD of recipient origin.
APA, Harvard, Vancouver, ISO, and other styles
8

Chakupurakal, Geothy. "Preclinical studies of adenovirus-specific T-cells for adoptive transfer to haemopoietic stem cell transplant recipients." Thesis, University of Birmingham, 2011. http://etheses.bham.ac.uk//id/eprint/2883/.

Full text
Abstract:
Allogeneic stem cell transplantation (SCT) is the only curative treatment option for many haematological malignancies. Adenovirus (Ad) infections are a significant cause of morbidity and mortality post SCT. Lack of effective anti-viral treatment for Ad disease has led to the development of adoptive immunotherapy of Ad-specific T-cells as a promising therapeutic option for patients in this setting. The aim of this project was to establish preclinical criteria for the development of a clinical trial comparing two T-cell enrichment methods- multimer selection and cytokine secretion selection to enrich Ad-specific T-cells for the purposes of adoptive transfer directly without the need for in vitro culture. Eight pHLA tetramers containing HLA class I restricted Ad epitopes were generated and their ability to identify and enrich Ad-specific T-cells investigated. HLA A*01 TDL tetramer consistently detected T-cells in all (13/13) healthy adult donors screened. Frequency and enrichement of Ad-specific T-cells by cytokine secretion and selection was also investigated. Despite the low frequency of Ad-specific T-cells, clinical grade enrichment was feasible by both methods. T-cells selected by both methods were then characterised for homing and proliferative potential. Ad-specific T-cells identified by either method had a high proliferative potential, possessed a novel minimally differentiated memory phenotype, were cytotoxic towards Ad species responsible for infections in SCT recipients and capable of limiting virus replication. In conclusion, Ad-specific T-cells enriched by multimer selection or cytokine secretion selection are suitable for adoptive transfer to patients with Ad infection following HSCT. Both methods also allow the monitoring of Ad-specific immune reconstitution after adoptive transfer.
APA, Harvard, Vancouver, ISO, and other styles
9

Shindo, Takero. "Growth and differentiation advantages of CD4[+]OX40[+] T cells from allogeneic hematopoietic stem cell transplantation recipients." Kyoto University, 2008. http://hdl.handle.net/2433/135836.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tector, A. Joseph. "Discordant liver xenotransplantation in recipients with liver failure." Thesis, McGill University, 2002. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=84439.

Full text
Abstract:
Liver xenotransplantation could eliminate the liver donor shortage, but currently it is not possible because of a lack of understanding of liver xenograft rejection. Hyperacute xenograft rejection is initiated by the binding of preformed naturally occurring xenoreactive antibodies (XNA) to the xenograft endothelium. The XNA bind to the xenograft endothelium, leading to complement-mediated endothelial injury.<br>Liver xenotransplantation will be initially offered to patients with severe liver failure as a bridge to a human liver transplantation. The hypothesis tested in this thesis is that hyperacute rejection of liver xenografts placed into recipients with liver failure will be diminished because of the complement deficiency that accompanies liver failure. The experiments described in this thesis detail the development of an in vitro pig-to-human liver xenotransplant model incubating cultured pig hepatic endothelial cells (PHEC) and human serum in culture. We showed that either classical or alternative complement pathways could initiate endothelial injury. Next we developed the dog-to-pig liver xenograft model and characterized the lethal coagulopathy that results from hyperacute rejection. The coagulopathy results from the lack of function of platelets as well as their disappearance from the circulation. We then used the galactosamine induced liver injury model in porcine recipients of canine liver xenografts to demonstrate that hyperacute rejection in the setting of liver failure is diminished. We showed that; tissue injury, coagulopathy and platelet defect, and endothelial injury were diminished. Our experiments suggested that the cause of the decreased injury was the lack of complement in the pigs with galactosamine induced liver injury since the XNA levels were no different than in control animals. Our final experiments evaluated serum from patients with liver failure and compared the injury caused by incubation with PHEC. Serum from the liver failure patients had similar levels of XNA when compared with normal subjects, but had less complement activity, and less C3 and C4. Incubation of liver failure serum with PHEC caused much less injury and complement activation than serum from control subjects. The results in this thesis suggest that liver failure will have a significant impact on liver xenograft rejection, helping to diminish hyperacut
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cell recipient"

1

Grossi, Danny. Long-term engraftment of bone marrow stromal cells in unconditioned murine recipients. National Library of Canada, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Strasfeld, Lynne. While the T Cells Were Sleeping. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0215.

Full text
Abstract:
These case studies illustrate infections encountered in hospitals among patients with compromised immune systems. As a result of immunocompromise, the patients are vulnerable to common and uncommon infections. These cases are carefully chosen to reflect the most frequently encountered infections in the patient population, with an emphasis on illustrations and lucid presentations to explain the state-of-the-art approaches in diagnosis and treatment. Common and uncommon presentations of infections are presented while the rare ones are not emphasized. The cases are written and edited by clinicians and experts in the field. Each of these cases highlight the immune dysfunction that uniquely predisposed the patient to the specific infection, and the cases deal with infections in the cancer patient, infections in the solid organ transplant recipient, infections in the stem cell recipient, infections in patients receiving immunosuppressive drugs, and infections in patients with immunocompromise that is caused by miscellaneous conditions.
APA, Harvard, Vancouver, ISO, and other styles
3

Wingard, John R. Introduction. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0300.

Full text
Abstract:
This chapter starts by explaining that the goal of allogeneic stem cell transplantation is the establishment of donor hematopoiesis and immunity in the recipient to treat an antecedent marrow failure disorder or to achieve a graft-versus-cancer effect to treat a neoplastic disease. The goal of autologous hematopoietic stem cell transplant (HSCT) is very different from allogeneic HSCT. In autologous HSCT, the goal of the graft is simpler: it is to rescue the myelotoxic effects of high-dose chemotherapy. Neutropenia is shorter, cellular immunodeficiency is less profound, and immune reconstitution is quicker. Infectious exposures before transplant play an important role after transplant. Although an infection may be effectively treated and under good control before transplant, reactivation may occur after transplant. The search for risk factors that can identify individuals at greatest risk for various types of infection has led to the identification of neutropenia, lymphopenia (or low CD4+ cell counts), low levels of immunoglobulin, and GVHD, prior infection by organisms that may persist in the recipient or donor, and a number of other factors in certain situations. The chapter concludes that one of the biggest challenges is distinguishing infection from some other noninfectious etiology of a syndrome.
APA, Harvard, Vancouver, ISO, and other styles
4

Chandrasekar, Pranatharthi H., ed. Infections in the Immunosuppressed Patient. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.001.0001.

Full text
Abstract:
These case studies illustrate infections encountered in hospitals among patients with compromised immune systems. As a result of immunocompromise, the patients are vulnerable to common and uncommon infections. These cases are carefully chosen to reflect the most frequently encountered infections in the patient population, with a specific emphasis on illustrations and lucid presentations to explain state-of-the-art approaches in diagnosis and treatment. Common and uncommon presentations of infections are presented while the rare ones are not emphasized. The cases are written and edited by clinicians and experts in the field. Each case highlights the immune dysfunction that uniquely predisposed the patient to the specific infection, and the cases deal with infections in the cancer patient, infections in the solid organ transplant recipient, infections in the stem cell recipient, infections in patients who receive immunosuppressive drugs, and infections in patients with immunocompromise that is caused by miscellaneous conditions.
APA, Harvard, Vancouver, ISO, and other styles
5

Pereira, Edwin C. Leg Edema Woes. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0001.

Full text
Abstract:
These case studies illustrate infections encountered in hospitals among patients with compromised immune systems. As a result of immunocompromise, the patients are vulnerable to common and uncommon infections. These cases are carefully chosen to reflect the most frequently encountered infections in the patient population, with an emphasis on illustrations and lucid presentations to explain state-of-the-art approaches in diagnosis and treatment. Common and uncommon presentations of infections are presented while the rare ones are not emphasized. The cases are written and edited by clinicians and experts in the field. Each of these cases highlights the immune dysfunction that uniquely predisposed the patient to the specific infection, and the cases deal with infections in the cancer patient, infections in the solid organ transplant recipient, infections in the stem cell recipient, infections in patients receiving immunosuppressive drugs, and infections in patients with immunocompromise that is caused by miscellaneous conditions.
APA, Harvard, Vancouver, ISO, and other styles
6

Tang, Patrick, and R. Gregory Bociek. Doctor, I’m Sick Again and Again. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0002.

Full text
Abstract:
These case studies illustrate infections encountered in hospitals among patients with compromised immune systems. As a result of immunocompromise, the patients are vulnerable to common and uncommon infections. These cases are carefully chosen to reflect the most frequently encountered infections in the patient population, with an emphasis on illustrations and lucid presentations to explain state-of-the-art approaches in diagnosis and treatment. Common and uncommon presentations of infections are presented while the rare ones are not emphasized. The cases are written and edited by clinicians and experts in the field. Each of these cases highlights the immune dysfunction that uniquely predisposed the patient to the specific infection, and the cases deal with infections in the cancer patient, infections in the solid organ transplant recipient, infections in the stem cell recipient, infections in patients receiving immunosuppressive drugs, and infections in patients with immunocompromise that is caused by miscellaneous conditions.
APA, Harvard, Vancouver, ISO, and other styles
7

Nazinitsky, Allison L., and Steven J. Lawrence. What’s Lurking Beyond the Barricade? Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0003.

Full text
Abstract:
These case studies illustrate infections encountered in hospitals among patients with compromised immune systems. As a result of immunocompromise, the patients are vulnerable to common and uncommon infections. These cases are carefully chosen to reflect the most frequently encountered infections in the patient population, with an emphasis on illustrations and lucid presentations to explain state-of-the-art approaches in diagnosis and treatment. Common and uncommon presentations of infections are presented while the rare ones are not emphasized. The cases are written and edited by clinicians and experts in the field. Each of these cases highlights the immune dysfunction that uniquely predisposed the patient to the specific infection, and the cases deal with infections in the cancer patient, infections in the solid organ transplant recipient, infections in the stem cell recipient, infections in patients receiving immunosuppressive drugs, and infections in patients with immunocompromise that is caused by miscellaneous conditions.
APA, Harvard, Vancouver, ISO, and other styles
8

Mullane, Kathleen M. Alimentary Antimicrobial Apocalypse. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0004.

Full text
Abstract:
These case studies illustrate infections encountered in hospitals among patients with compromised immune systems. As a result of immunocompromise, the patients are vulnerable to common and uncommon infections. These cases are carefully chosen to reflect the most frequently encountered infections in the patient population, with an emphasis on illustrations and lucid presentations to explain state-of-the-art approaches in diagnosis and treatment. Common and uncommon presentations of infections are presented while the rare ones are not emphasized. The cases are written and edited by clinicians and experts in the field. Each of these cases highlights the immune dysfunction that uniquely predisposed the patient to the specific infection, and the cases deal with infections in the cancer patient, infections in the solid organ transplant recipient, infections in the stem cell recipient, infections in patients receiving immunosuppressive drugs, and infections in patients with immunocompromise that is caused by miscellaneous conditions.
APA, Harvard, Vancouver, ISO, and other styles
9

Neemann, Kari. Not Appendicitis in a Neutropenic Host. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0005.

Full text
Abstract:
These case studies illustrate infections encountered in hospitals among patients with compromised immune systems. As a result of immunocompromise, the patients are vulnerable to common and uncommon infections. These cases are carefully chosen to reflect the most frequently encountered infections in the patient population, with an emphasis on illustrations and lucid presentations to explain state-of-the-art approaches in diagnosis and treatment. Common and uncommon presentations of infections are presented while the rare ones are not emphasized. The cases are written and edited by clinicians and experts in the field. Each of these cases highlights the immune dysfunction that uniquely predisposed the patient to the specific infection, and the cases deal with infections in the cancer patient, infections in the solid organ transplant recipient, infections in the stem cell recipient, infections in patients receiving immunosuppressive drugs, and infections in patients with immunocompromise that is caused by miscellaneous conditions.
APA, Harvard, Vancouver, ISO, and other styles
10

Tang, Patrick, and R. Gregory Bociek. Lung Lesions, Skin Lesions, Brain Lesions … Oh My. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0006.

Full text
Abstract:
These case studies illustrate infections encountered in hospitals among patients with compromised immune systems. As a result of immunocompromise, the patients are vulnerable to common and uncommon infections. These cases are carefully chosen to reflect the most frequently encountered infections in the patient population, with an emphasis on illustrations and lucid presentations to explain state-of-the-art approaches in diagnosis and treatment. Common and uncommon presentations of infections are presented while the rare ones are not emphasized. The cases are written and edited by clinicians and experts in the field. Each of these cases highlights the immune dysfunction that uniquely predisposed the patient to the specific infection, and the cases deal with infections in the cancer patient, infections in the solid organ transplant recipient, infections in the stem cell recipient, infections in patients receiving immunosuppressive drugs, and infections in patients with immunocompromise that is caused by miscellaneous conditions.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cell recipient"

1

Hunziker, Thomas. "Cell Delivery on Recipient Skin." In Vitiligo. John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781118937303.ch40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Eichelberger, Carrie, and Valerie I. Brown. "HSCT Recipient Pretransplantation Evaluation." In Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-63146-2_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Macris, Paula Charuhas, and Kerry K. McMillen. "Nutrition Support of the Hematopoietic Cell Transplant Recipient." In Thomas’ Hematopoietic Cell Transplantation. John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118416426.ch99.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Marty, Francisco M., and Lindsey R. Baden. "Infection in the Hematopoietic Stem Cell Transplant Recipient." In Hematopoietic Stem Cell Transplantation. Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-438-4_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Akirav, Eitan M., and Kevan C. Herold. "Prevention of Islet Graft Rejection and Recipient Tolerization." In Stem Cell Therapy for Diabetes. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-366-4_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chowdhury, Mita Roy, Martha Lassiter, Rizwan Javed, and Satyendra Katewa. "Hematopoietic Stem Cell Donor and Recipient Evaluation." In Contemporary Bone Marrow Transplantation. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-319-64938-2_29-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chowdhury, Mita Roy, Martha Lassiter, Rizwan Javed, and Satyendra Katewa. "Hematopoietic Stem Cell Donor and Recipient Evaluation." In Contemporary Bone Marrow Transplantation. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-36358-1_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Halter, Joerg P., Nina Worel, and Jakob R. Passweg. "Donor/Recipient Selection, Work-Up, and Safety." In Establishing a Hematopoietic Stem Cell Transplantation Unit. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-59358-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Baden, Lindsey, and Robert H. Rubin. "Infection in the Hematopoietic Stem Cell Transplant Recipient." In Stem Cell Transplantation for Hematologic Malignancies. Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-733-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Linder, Kathleen, and Kevin Gregg. "Visual Loss in a Hematopoietic Stem Cell Transplant Recipient." In The Infectious Disease Diagnosis. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-64906-1_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cell recipient"

1

Gitman, Melissa R., Shirish Huprikar, and Gopi Patel. "Trichosporon Asahii Pulmonary Infection In A Hematopoietic Stem Cell Transplant Recipient." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a5467.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Huntington, Scott F., John C. Callison, and Elisabeth D. Willers. "Recurrent Pleuritis And Pericarditis In An Autologous Stem-cell Transplant Recipient On Sirolimus." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4626.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Madden, Kate, Stefanie Gauget, Jennifer Wu, Christine Duncan, and Meredith van der Velden. "A Case Of Acute Aspergillus Tracheobronchitis In A Recent Stem Cell Transplant Recipient." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4602.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hinzman, Charles Phillip, Shivani Bansal, Yaoxiang Li, et al. "Abstract 2668: Pancreatic cancer cell extracellular vesicles drive the unfolded protein response in recipient normal pancreas cells." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-2668.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lusher, J. M., L. M. Aledort, S. Sarnaik, and J. Mosley. "HIV STATUS, T CELL SUBSETS, BLOOD PRODUCT USE, AND HEMATOLOGIC ABNORMALITIES IN CONGENITAL COAGULATION DISORDERS (CCD)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644681.

Full text
Abstract:
Data are presented on 485 subjects with CCDtreated with blood products at entry into a cooperative study of blood product safety; 376 subjects had hemophilia A, 86 had hemophilia B,and 23 had von Willebrand*is disease (vWD) . Anti-HIV was detected in a total of 323 (66.7%)subjects. Of those treated with pooled product303/397 (76.4%) had anti-HIV; of these, 256/316 (81%) had hemo. A, 44/76 (57.9%) had hemo. B, and 3/5 (60%) had vWD. Of those treated withunpooled products 20/88 (22.7%) had anti-HIV;of these 17/60 (28.3%) had hemo. A; 0 of 10 hadhemo. B, and 3/18 (16.6%) had vWD.The percent of T4 cells in all groups studied were significantly lower in anti-HIV (+) as compared toanti-HIV (-) patients (26% vs 42%) (p=0.0001).T4/T8 ratios demonstrated significant differences in all groups treated (p=0.001) when comparing anti-HIV (+) with anti-HIV (-). However, F VIII concentrate recipients who are anti-HIV(-) have significantly lower T4/T8 when compared to controls (p=0.0001) and single pooled F VIII deficient recipient patients (p=0.0264). Mean platelet counts, WBC, ALC, and Hgb were all significantly lower in anti-HIV ( + ) subjects (p &lt;.001,=.0002,=.002, and =.02) A significantly higher % of anti-HIV (+) subjects had abnormally low WBC, ALC and platelet counts (table). In summary, anti-HIV (+) and lower T4/T8ratios were related to type of blood product used, being seen significantly less frequently in patients receiving only unpooled product. Thrombopenia, leucopenia, and lymphopenia were seen more frequently in anti-HIV (+) patients. _
APA, Harvard, Vancouver, ISO, and other styles
6

Erat, Tuğba, Aysun Yahşi, Tuğçe Tural Kara, et al. "P263 Nosocomial pneumonia caused by legionella pneumophila in a paediatric hematopoietic stem cell transplantation recipient for thalassemia major." In 8th Europaediatrics Congress jointly held with, The 13th National Congress of Romanian Pediatrics Society, 7–10 June 2017, Palace of Parliament, Romania, Paediatrics building bridges across Europe. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2017. http://dx.doi.org/10.1136/archdischild-2017-313273.351.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Terres, Hilario, Sandra Chavez, Raymundo Lopez, Arturo Lizardi, Araceli Lara, and Juan R. Morales. "Irreversibility and Second Law Analysis in a Solar Cooker Box-Type." In ASME 2015 9th International Conference on Energy Sustainability collocated with the ASME 2015 Power Conference, the ASME 2015 13th International Conference on Fuel Cell Science, Engineering and Technology, and the ASME 2015 Nuclear Forum. American Society of Mechanical Engineers, 2015. http://dx.doi.org/10.1115/es2015-49699.

Full text
Abstract:
In this work, four different arrangements of solar cooker box-type with internal reflectors results, for irreversibility and second law efficiency are presented. The solar cooker has two glasses in its cover to diminish the losses of heat radiation and convection, which in turn creates the hot house effect inside the cooker. The interior of the cooker has flat mirrors placed at different angles to reflect the solar radiation toward recipient with water. The obtained results are based on the heated water temperatures. These are obtained by means of numerical simulation, which in turn allows the comparison under identical conditions for the cookers. The results reveal that the energy reaching the cookers, less than 5%, is used in the water heating process. Most of the available energy is “stored” into the cooker glass cover, which shows the need for further work on improving cover materials in order to diminish such a situation.
APA, Harvard, Vancouver, ISO, and other styles
8

Snyder, M. E., T. Tabib, I. Popescu, et al. "Clonal Expansion and Persistence of Recipient-Derived Alloreactive T Cells in the Lungs of Transplant Recipients." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1321.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Freeman, L., V. Hornsey, D. S. Pepper, P. R. Foster, L. Winkelman, and J. Dawes. "PROTEIN AGGREGATES IN HEATED BLOOD PRODUCTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644019.

Full text
Abstract:
Heating of blood products to reduce viral infectivity is now a standard practice. Such treatment may also modify the constituent proteins, reducing their activity or altering their structure with potentially harmful consequences for the recipient. Partially denatured proteins frequently form aggregates, which are often immunogenic and could precipitate immune complex formation, allergic reactions and kidney damage. In addition they may contribute to the development of AIDS after HIV infection by inducing a persistent state of T-cell activation.Protein aggregate formation in factor VIII and factor IX (II + X) concentrates has been investigated by fast protein liquid chromatography (FPLC), which proved to be a rapid, convenient method for this purpose. Freeze-drying alone resulted in aggregate formation in intermediate purity FVIII concentrates, but not in FIX concentrates. However, aggregates were detected after heating the FIX concentrate at 80°C for 72h in the dry state. Dry heating of intermediate purity FVIII concentrates to 68°C for 24h also increased the content of protein aggregates, which contained fibrinogen and fibronectin but little IgG. In this product, the aggregate content after heating correlated with total protein concentration. A higher purity FVIII concentrate selectively depleted in fibrinogen and fibronectin also contained protein aggregates after freeze-drying, but heating this product at 80°C for 72h resulted in a relatively small increase in aggregate content. Haemophiliacs receiving regular injections of heated concentrates are constantly exposed to protein aggregates. They should be monitored for any harmful effects, and manufacturers should aim to reduce the aggregate content of their products.
APA, Harvard, Vancouver, ISO, and other styles
10

Zhang, Z., C. Wang, A. S. Niven, and H. Yadav. "Diffuse Alveolar Hemorrhage in Stem Cell Transplant Recipients." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1673.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cell recipient"

1

Fast, L. D., C. R. Valeri, and J. P. Crowley. Immune Responses to MHC Homozygous Lymphoid Cells in Murine F1 Hybrid Recipients: Implications for Transfusion Associated Graft-Versus Host Disease. Defense Technical Information Center, 1994. http://dx.doi.org/10.21236/ada360361.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cell recipient' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography